Recent Updates
Recently added Catalysts

Fragmin

Phase 4FDA approved

Chronic Renal Failure | Small molecule | Nephrology |Pfizer, Inc.|Trials Updated: Dec 19, 2018

Fragmin development status

FDA approval on record Mar 30, 1999
Approval holderPfizer
ApplicationNDA020287
Highest phase Phase 4 (NCT00655122)
Phase scored for PFEPhase 3
Registered trials 6 across 1 sponsor since May 2007

Label indication FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the… FDA label

Fragmin target and mechanism

ModalitySmall molecule

Also known as Dalteparin sodium, Fragmin (dalteparin sodium )

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials3
Total Enrollment490

FDA Designations

No designations recorded

Fragmin clinical trials

Fragmin · 3 trials · 2 indications

Phase 3 1Phase 2 2
NCT01879618Use Of Fragmin In HemodialysisChronic Renal Failure
COMPLETED152 Analytics
PHASE3COMPLETED
Use Of Fragmin In Hemodialysis
Chronic Renal FailureUnlock trial analytics

Study Endpoints

Primary Endpoints

Mean Percent of Successful HD Sessions
20 HD sessions (up to 4 hours)

A successful HD session is defined in terms of efficacy of the drug where the HD session had completed as planned: there was no premature termination due to Grade 3 or 4 clotting or saline flush to prevent the loss of the extracorporeal circuit due to clotting; it was not possible to return the participant's blood or assess the exact extent of clotting. HD sessions which terminated prematurely due to Grade 1 or 2 clotting, safety event, machine failure, or access site displacement were excluded from the analysis. The point estimate and 95% CI were computed based on generalized estimating equation (GEE) model for clustered binomial data.

Number of All Hemorrhages
Baseline to Week 24 (end of treatment [EOT]) or early termination (ET)

Major hemorrhages: defined as fatal bleeding, clinically overt bleeding causing a fall in hemoglobin greater than or equal to 20 gram (g)/litre (L) (2 g/ decilitre \[dL\]), clinically overt bleeding leading to transfusion of greater than or equal to 2 units of whole blood or red cells, or symptomatic bleeding in areas of special concern (intracranial, retroperitoneal, intraocular, intraspinal, pericardial, intramuscular with compartmental syndrome, or intraarticular). Minor hemorrhages: defined as bleeding that did not meet the definition of major bleeding.

Number of Major Hemorrhages
Baseline to Week 24 (EOT) or ET

Major hemorrhages: defined as fatal bleeding, clinically overt bleeding causing a fall in hemoglobin greater than or equal to 20 g/L (2 g/dL), clinically overt bleeding leading to transfusion of greater than or equal to 2 units of whole blood or red cells, or symptomatic bleeding in areas of special concern (intracranial, retroperitoneal, intraocular, intraspinal, pericardial, intramuscular with compartmental syndrome, or intraarticular).

Number of Minor Hemorrhages
Baseline to Week 24 (EOT) or ET

Minor hemorrhages: defined as bleeding that did not meet the definition of major bleeding.

Number of Clinically Relevant Minor Hemorrhages
Baseline to Week 24 (EOT) or ET

Clinically relevant minor (non-major) bleeding was defined as any bleeding compromising hemodynamics, leading to hospitalization, subcutaneous haematoma more than 25 cm\^2, intramuscular haematoma, epistaxis lasting for more than 5 minutes, spontaneous gingival bleeding, macroscopic hematuria and gastrointestinal hemorrhage (including at least 1 episode of melaena or hematemesis), rectal blood loss, hemoptysis, and any other bleeding with clinical consequences.

Number of Trivial Hemorrhages
Baseline to Week 24 (EOT) or ET

Trivial bleeding was defined as all minor bleeding that did not meet the definition of clinically relevant minor bleeding.

Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing
Week 24 [end of treatment (EOT)] or early termination

University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure\>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure\<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure\>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure\<=30 mmHg and UT grade and stage 2C.

Secondary Endpoints

Mean Percent of HD Sessions With an Acceptable Dose
20 HD sessions (up to 4 hours)
Number of Participants With Intact Skin Healing
Baseline through Week 24 (EOT) or ET
Number of Participants With Improved Ulcer Healing
Baseline through Week 24 (EOT) or ET
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
FragminEXPERIMENTALFragmin given according to the flexible dosing regimen outlined in the protocol
ActiveEXPERIMENTALActive study treatment
PlaceboPLACEBO_COMPARATORPlacebo

Interventions

NameTypeDescription
FragminDRUGvariable dosing regimen
Fragmin/ Dalteparin SodiumDRUGPre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
Placebo for Fragmin/ Dalteparin SodiumDRUGPre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: * chronic renal failure on hemodialysis Exclusion Criteria: * significant comorbidities that would prevent a patient from completing the trial

Countries:CanadaAustriaBelgiumCzechiaDenmarkGermanyGreeceItalyNorwayPolandRussiaSwedenUkraineUnited KingdomFinlandLithuaniaSpain
Unlock Eligibility Criteria

Frequently asked questions about Fragmin

What is Fragmin?

Fragmin is a small molecule drug developed by Pfizer, Inc. (ticker PFE). It has been studied in clinical trials for chronic renal failure and diabetic foot ulcer, within the nephrology therapeutic area. Fragmin is also known by the names dalteparin sodium and dalteparin.

What is Fragmin used for in chronic renal failure?

Fragmin has been studied for use in hemodialysis in patients with chronic renal failure. A Phase 3 trial titled Use Of Fragmin In Hemodialysis evaluated the drug in this setting in Canada, enrolling 152 participants aged 18 years and older. The trial has been completed.

Who makes Fragmin?

Fragmin is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer sponsored the clinical trials evaluating Fragmin in chronic renal failure and diabetic foot ulcer.

What phase is Fragmin in?

Fragmin has been evaluated in Phase 3 and Phase 2 clinical trials. The Phase 3 study examined Fragmin in hemodialysis for chronic renal failure, while two Phase 2 studies examined Fragmin in diabetic patients with neuroischaemic foot ulcers. All listed trials are completed.

What clinical trials is Fragmin in?

Fragmin has been studied in completed trials including NCT01879618, a Phase 3 study of Fragmin in hemodialysis for chronic renal failure, and NCT00765063 and NCT00662831, two Phase 2 studies of Fragmin in the treatment of neuroischaemic foot ulcers in diabetic patients. Total enrollment across these trials was 338 participants.

Is Fragmin the same as dalteparin sodium?

Yes, Fragmin is also known as dalteparin sodium and dalteparin. These names refer to the same small molecule drug developed by Pfizer, Inc. (ticker PFE), which has been studied in chronic renal failure and diabetic foot ulcer.